This is a smart article on valuation for a biotech
Post# of 36537
https://www.nature.com/bioent/2003/030101/ful...1-813.html
Since NGIO shares aren’t listed as we await to see the spin-off, they have no enterprise (or any type of) value. But, we did see NGIO shares used as a form of currency. It’s exciting that the spin-off and potential merger is close.